VINC: Vincerx Price/Earnings to Growth Ratio

Corporate company logo of Vincerx (VINC)

The development of targeted blood cancer drugs is independent of economic cycles and seasons. By comparing the P/E multiplier to earnings growth on GURU.Markets, we see that the 0.00 value captures the metric level, while a liquidity deficit triggers share dilution for Vincerx Pharma, Inc. (VINC). The primary threats involve potential clinical trial failures and a lack of funds to complete them.

Vincerx Pharma, Inc. - VINC Price/Earnings to Growth Ratio (period 07/04/2022 - 05/31/2025)

Analytical breakdowns for Vincerx (VINC)

- share price and consensus valuation forecast:
Price Performance Chart Vincerx Pharma|VINC - Analyst Consensus Forecast
- market capitalization information:
Market Value Vincerx Pharma|VINC - Total Company Value
- issuer book value statistics:
Net Assets per Single Share Vincerx Pharma|VINC - Company Book Value|Market-to-Book Ratio vincerx.com|VINC - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Vincerx Pharma, Inc.|VINC - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Vincerx|VINC - Company Total Debt|Debt to Book Capitalization Ratio Vincerx Pharma, Inc.|VINC - Company Long-Term Debts|Short-Term Debt Volume Vincerx Pharma|Immediate Liquidity Ratio vincerx.com
- financial results and valuation multiples details:
VINC - Net Profit|Future Profit Vincerx Pharma, Inc.|VINC - P/E Multiple|Projected Price to Earnings Ratio Vincerx Pharma Inc.|VINC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Vincerx Pharma, Inc.|VINC - Operating profit before deduction of amortization|Earnings per share for the last 12 months Vincerx Pharma|VINC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months vincerx.com|VINC - Earnings per share growth in current year|Net earnings per share change forecast for next year Vincerx Pharma, Inc.
- total revenue and sales volume data:
VINC - Revenue and Sales Volume|Company Future Revenue Vincerx Pharma|VINC - P/S Multiple|Forward P/S Multiple Vincerx Pharma
Summary company analytics:Vincerx VINC
Mass-produced product of Vincerx Pharma Inc.

The oncology drug manufacturing outsourcing model minimizes capital expenditures for Vincerx Pharma, Inc. (VINC), ensuring high operating profit flexibility. By analyzing the PEG ratio, an investor assesses the relationship between the P/E multiple and annual earnings growth: values below one on this chart confirm a fundamental undervaluation of the asset relative to its growth trajectory, signaling high potential for price appreciation.

Competing companies

TGTX (TG Therapeutics Corp) - Growth-Adjusted Payback Ratio|PEG Multiple ACLX (Arcellx)|discmedicine.com - Price/Earnings to Growth Ratio|SNDX - Price/Earnings to Growth Ratio|KURA: Price/Earnings to Growth Ratio|adctherapeutics.com (ADCT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Foghorn (FHTX)|VOR (Vor Biopharma) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Nkarta, Inc. NKTX|PEG Multiple COEP|Actinium Pharmaceuticals, Inc. - Growth-Adjusted P/E Ratio|PEG Multiple ESLA (estrellabio.com)|CASI - Price/Earnings to Growth Multiple|Marker Therapeutics - PEG Multiple|INAB (in8bio.com) - Growth-Adjusted P/E Ratio|ERNA: PEG Multiple|GT Biopharma - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Aptose Biosciences Inc|BPTH - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio MEI Pharma Corp (MEIP)